Publications in peer-reviewed journals:

  1. Zafari Z, Lynd LD, FitzGerald JM, Sadatsafavi M, “Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study”, J Allergy Clin Immunol (JACI), 2014.
  2. Zafar Zafari, Don D. Sin, Dirkje S. Postma, Claes-Göran Löfdahl, Judith Vonk, Stirling Bryan, Stephen Lam, C. Martin Tammemagi, Rahman Khakban, S.F. Paul Man, Donald Tashkin, Robert A. Wise, John E. Connett, Bruce McManus, Raymond Ng, Zsuszanna Hollander, Mohsen Sadatsafavi, “Individualized prediction of lung function decline in COPD”, Canadian Medical Association Journal (CMAJ), 2016.
  3. Zafari Z, Thorlund K, FitzGerald JM, Marra CA, Sadatsafavi M, “Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes”, Pharmacoeconomics, 2014.
  4. Zafari Z, Sadatsafavi M, Marra CA, Chen W, Fitzgerald JM, “Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma”, PLOS ONE 2016.
  5. Zafari Z, Bryan S, Sin D, Conte T, Khakban R, Sadatsafavi M, “A systematic review of health economics simulation models of chronic obstructive pulmonary disease”, Value in Health, 2016.
  6. Sadatsafavi M, Bansback N, Zafari Z, Najafzadeh M, Marra C, “Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information”, Value Health, 2013.
  7. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, Keskimäki I, Badrick E, Renehan AG, Buchan IE, Bowker SL, Minhas-Sandhu JK, Zafari Z, Marra C, Johnson JA, Stricker BH, Uitterlinden AG, Hofman A, Ruiter R, de Keyser CE, MacDonald TM, Wild SH, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network Epidemiology Group; Diabetes and Cancer Research Consortium, “Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis”, Diabetologia, 2015.
  8. Khakban A, Sin DD, FitzGerald JM, Ng R, Zafari Z, McManus B, Hollander Z, Marra CA, Sadatsafavi M, “10-Year Trends in Direct Costs of COPD: A Population Based Study”, Chest 2015.
  9. Sadatsafavi M, Lynd LD, De Vera MA, Zafari Z, FitzGerald JM, “One-year outcomes of inhaled controller therapies added to systemic corticosteroids after asthma-related hospital discharge”, Respir Med, 2015.
  10. Thorlund K, Zafari Z, Druyts E, Mills EJ, Sadatsafavi M, “The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis-a case study of pharmacotherapies for moderate to severe COPD”, Cost Eff Resour Alloc, 2014.
  11. Abdulrahman Alshabanat A, Zafari Z, Dairi M, Albanyan O, Fitzgerald JM, “Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta-analysis”, PLOS ONE, 2015.
  12. Chen W, Marra C, Lynd, L, Fitzgerald JM, Zafari, Z, Sadatsafavi M, “The natural history of severe asthma and influences of early risk factors: a population-based cohort study”, Thorax, 2016.
  13. Sadatsafavi M, Sin D, Zafari Z, Criner G, Connett J E, Woodruff P, Lazarus S, Han M, Martinez F, Albert R, “The association between exacerbation rate and severity in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model”, American Journal of Epidemiology (AJE), 2016.
  14. Tsao N, Khakban A, Gastonguay L, Zafari Z, Lynd L, Marra C, “Opinions and preferences of British Columbia pharmacists and physicians on medication management services”, Canadian Pharmacists Journal, 2016.
  15. Khakban A, Mohammadi T, Lynd L, Mabbott D, Bouffet E, Gastonguay L, Zafari Z, Malkin D, Taylor M, Marra C, “Societal Preferences in the Treatment of Pediatric Medulloblastoma: Balancing Risk of Death and Quality of Life”, Pediatric Blood & Cancer, 2016.
  16. Zafari Z., Fitzgerald MJ, Sadatsafavi M., “Comparing costs and health outcomes of tiotropium versus omalizumab for severe uncontrolled allergic asthma in US”, under review.
  17. Zafari Z, Sadatsafavi M, Chen W, Fitzgerald M, “The projected economic and health burden of sub-optimal asthma control in Canada”, under review.
  18. Vogel M, Nikoo M, Choi F, Burghardt J, Song MJ, Zafari Z, Tabiova K, Frank A, Barbic S, Guh D, Anis A, Schütz C, Jang K, Krausz M, “Employment and ability to work among participants in treatment with highly potent opioids”, under review.
  19. Sadatsafavi M, Gustafson P, Zafari Z, Sin D, “Moving beyond the ROC curve to visualize and quantify the clinical and policy consequences of implementing markers”, under review.
  20. Zafari, J. Tavakoli, “New Approach for Fuzzy Control and Analysis of Queueing System with Flexible Service Time”, IMECS 2011, ISBN: 978-988-19251-2-1.
  21. Zafari Z, Muennig PA, “Cost-effectiveness of Moving to Opportunity housing vouchers in US”, under review.
  22. Kim S, Zafari Z, Bellanger M, Muennig PA, “The cost-effectiveness of capping freeways for use as parks in the name of population health: the Cross-Bronx Expressway case study”, revised with minor revisions in American Journal of Public Health.
  23. Li S, Jiao B, Zafari Z, Muennig PA, “The cost-effectiveness of speed limit enforcement cameras: A modeling study in New York City”, under review.
  24. Ruggeri K, Ivanović N, Razum J, Kácha O, Menezes IG, Zafari Z, Garcia-Garzon E, “An advance-based policy for managing global health access through medical travel”, under review.
  25. Abdulrahman Alshabanat A, Zafari Z, Dairi M, Albanyan O, Fitzgerald JM, “Updates on Asthma and COPD Overlap Syndrome (ACOS)”, under review.
  26. Zafari Z, Jiao B, Brian W, Li S, Muennig PA, “The trade off between aircraft flight efficiency and human health: a case study of aircraft noise in Queens, NY”, under review.
  27. Guo M, Etminan M, Zafari Z, Maberley D, “One year effectiveness study of Intravitreous Aflibercept in neovascular age-related macular degeneration: a meta-analysis”, under review.
  28. Jiao B, Zafari Z, Brian W, Ruggeri K, Li S, Muennig PA, “The cost-effectiveness of regulatory changes to noise around US airports”, under review.


  1. “Value of knowing individualized rate of lung function decline for a chronic obstructive pulmonary disease patient”, ready to be submitted to Medical Decision Making.
  2. “What do trends of despair over time tell us about mortality in the US”, ready to be submitted to Social Science and Medicine.
  3. “Effectiveness of ranibizumab in improving visual outcomes: results of a meta-analysis”, ready to be submitted to Acta Ophthalmologica.
  4. “Cost-effectiveness of deploying autonomous vehicles in post-earthquake response: a simulation study”, analyses done, manuscript writing ongoing.
  5. “The health effects and cost-effectiveness of bike shares: a New York City Citi Bike expansion case study”, analyses done, manuscript writing ongoing.
  6. “Cost-effectiveness of increasing minimum wage in the US”, analyses ongoing.

Published full reports:

  1. Zafari Z, Bryan S, Mitton C, Sadatsafavi M, “Evaluating the Cancer Risk Management Model (CRMM)–Colorectal Cancer Module”, accessible from Canadian task force.
  2. Sadatsafavi M, Zafari Z, Mitton C, Bryan S, “Evaluating the Cancer Risk Management Model (CRMM) – Lung Cancer Module”, Accessible from Canadian task force.

Published abstracts:

  1. Z. Zafari, S. Bryan, D. Sin, C. A. Marra, M. Sadatsafavi, “Value of characterizing heterogeneity in chronic obstructive pulmonary disease”, CADTH 2016, Ottawa, Canada.
  2. Z. Zafari, D. Sin, S. Bryan, M. Sadatsafavi, “The ideal biomarker to predict COPD exacerbations”, Am J Respir Crit Med 193;2016:A3508.
  3. Z. Zafari, M. Fitzgerald, C. Marra, M. Sadatsafavi, “Cost-effectiveness of tiotropium versus omalizumab for patients with severe uncontrolled asthma in US”, Am J Respir Crit Med 191;2015:A3712.
  4. Z. Zafari, D. D. Sin, S. Bryan, A. Khaban, B. M. McManus, R. Ng, Z. Hollander, M. Sadatsafavi, “Characterizing heterogeneity in lung function decline in COPD”, Am J Respir Crit Med 191;2015:A2434.
  5. Z. Zafari, D. Sin, S. Bryan, M. Sadatsafavi, “Informing micro-simulation economic models from patient-level data using mixed-model regression: theory and implications”, iHEA 2015, 11th World Congress, Milan Italy.
  6. A. Khakban, D. Sin, R. Ng, Z. Zafari, M. FitzGerald, B. McManus, Z. Hollander, C. Marra, Mohsen Sadatsafavi, “The Economic Burden of COPD in British Columbia from 2001 to 2010: A Population Based Study”, iHEA 2015, 11th Word Congress, Milan, Italy.
  7. Z. Zafari, M. Sadatsafavi, M. Fitzgerald, L. Lynd, C. Marra, “The Humanistic and Economic Impact of Following Evidence-Based Asthma Controller Therapy: A Simulation Study”, Value in Health, Volume 16, Issue 3 , Page A235, May 2013.
  8. Z. Zafari, K. Thorlund, M. Fitzgerald, L. Lynd, C. Marra, M. Sadatsafavi, “Impact of multiple treatment comparison meta-analysis on value of information evaluations: a case study of pharmacotherapies for chronic obstructive pulmonary diseases”, Value in Health, Volume 16, Issue 3 , Pages A26-A27, May 2013.
  9. G. Moullec, R. Rousseau, W. Chen, M. Sadatsafavi, Z. Zafari, A. Bekirov, M. J. FitzGerald, EBA study group, “Combined Effect of Psychological Distress and Asthma Control on Productivity Loss in Patients with Asthma: A Population-Based Study”, Am J Respir Crit Care Med, 189;2014:A2301.
  10. J. M. FitzGerald, W. Chen, C. A. Marra, L. Lynd, R. Rousseau, Z. Zafari, E. McClymont, M. Sadatsafavi, EBA Study Group, “The Influence of Asthma Impairment and Comorbidities on Health-Related Quality of Life”, Am J Respir Crit Care Med 189;2014:A1379.
  11. Amir Khakban, Louise Gastonguay, Larry Lynd, Tima Mohammadi, Zafar Zafari, Michael Taylor, Eric Bouffet, David Malkin, Carlo Marra, “Using best-worst scaling to evaluate trade-offs between quality of life and survival in pediatric medulloblastoma treatment”, Oral presentation in iHEA 2014, 10th world congress, Dublin, July 13-16, 2014.
  12. Anik R. Patel, Carlo A. Marra,  R. Scott Braithwaite , Zafar Zafari, Mia L. van der Kop, Richard T. Lester, “Cost-effectiveness of the WelTel mHealth program to improve adherence rates to antiretroviral therapy in Kenya”, Poster presentation in 6th Annual BCCDC Research Symposium, Vancouver, November 18-22, 2013.
  13. Z. Zafari, Y. Zhao, J. Tavakoli, “The exact tail asymptotic of a general random walk model in the first and fourth quadrants”, Canadian Operational Research Society (CORS), Niagara Falls, June 11-13, 2012.
  14. Z. Zafari, Y. Zhao, J. Tavakoli, “Analysis of exact tail asymptotic behaviour of the joint stationary distribution of the continuous-time JSQ (Joint the Shortest Queue)”, CanQueue 2011, Banff, Aug 26-28, 2011.
  15. Z. Zafari, J. Tavakoli “Healthcare Queueing System Fuzzy Control Approach for Reducing Sojourn Time”, INFORMS, Montreal, June 20-22, 2011.
  16. Zafar Zafari, “The Exact Tail Asymptotic Behaviour of the Joint Stationary Distributions of the Generalized Join the Shortest Queueing Model”, Master of Science Thesis 2012, University of British Columbia, Canada.